Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
Add more filters










Publication year range
1.
Osteoporos Int ; 32(8): 1609-1620, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33547487

ABSTRACT

It is unclear how physical activity intensity and vitamin D status are related to bone health in prepubertal children. We found positive associations between vitamin D status and moderate-to-vigorous physical activity with bone in boys and girls. This highlights the importance of lifestyle factors for skeletal health prepuberty. INTRODUCTION: The sex-specific independent and interactive associations of physical activity (PA) intensity and serum 25-hydroxyvitamin D (25(OH)D) levels with areal bone mineral density (aBMD) were investigated in prepubertal children. METHODS: The participants were 366 prepubertal Finnish children (190 boys, 176 girls) aged 6-8 years. Linear regression analysed the associations of sedentary time (ST), light PA (LPA), moderate PA (MPA), moderate-to-vigorous PA (MVPA) and vigorous PA (VPA) measured by accelerometery, and serum 25(OH)D with total body less head (TBLH) and lower-limb aBMD, measured by dual-energy X-ray absorptiometry. RESULTS: There was no interaction between PA intensity or serum 25(OH)D and sex with aBMD. MPA and MVPA were positively associated with TBLH and lower-limb aBMD (ß = 0.11, 95% CI 0.02-0.20, p = 0.01). Serum 25(OH)D was positively associated with TBLH and lower-limb aBMD (ß = 0.09, 95% CI 0.01-0.18, p = 0.03). There were no interactions between PA intensity and serum 25(OH)D with aBMD. CONCLUSION: Vitamin D status, MPA and MVPA levels in active prepubertal children were positively associated with aBMD. The influence of MVPA is due to the MPA component, though our findings regarding the role of VPA should be interpreted with caution, as shorter accelerometer epochs are needed to more accurately assess VPA. This study adds evidence to the promotion of MPA and behaviours to encourage optimal vitamin D status in supporting skeletal health in childhood, though these need not be used in conjunction to be beneficial, and a sex-specific approach is not necessary in prepubertal children. TRIAL REGISTRATION NUMBER: NCT01803776 . Date of registration: 4/03/2013.


Subject(s)
Bone Density , Exercise , Absorptiometry, Photon , Child , Female , Humans , Male , Sedentary Behavior , Vitamin D
2.
Plant Biol (Stuttg) ; 20(3): 426-432, 2018 May.
Article in English | MEDLINE | ID: mdl-29450949

ABSTRACT

The spatial deployment of lateral roots determines the ability of a plant to interact with the surrounding environment for nutrition and anchorage. This paper shows that besides the pericycle, the vascular cambium becomes active in Arabidopsis thaliana taproot at a later stage of development and is also able to form new lateral roots. To demonstrate the above, we implemented a two-step approach in which the first step leads to development of a secondary structure in A. thaliana taproot, and the second applies a mechanical stress on the vascular cambium to initiate formation of a new lateral root primordium. GUS staining showed PRE3, DR5 and WOX11 signals in the cambial zone of the root during new lateral root formation. An advanced level of wood formation, characterized by the presence of medullar rays, was achieved. Preliminary investigations suggest the involvement of auxin and two transcription factors (PRE3/ATBS1/bHLH135/TMO7 and WOX11) in the transition of some vascular cambium initials from a role as producers of xylem/phloem mother cells to founder cells of a new lateral root primordium.


Subject(s)
Arabidopsis Proteins/physiology , Arabidopsis/growth & development , Basic Helix-Loop-Helix Transcription Factors/physiology , Homeodomain Proteins/physiology , Plant Roots/growth & development , Transcription Factors/physiology , Arabidopsis/metabolism , Arabidopsis/ultrastructure , Indoleacetic Acids/metabolism , Plant Growth Regulators/physiology , Plant Roots/metabolism , Plant Roots/ultrastructure , Seedlings/growth & development
3.
Gene Ther ; 15(18): 1280-6, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18463689

ABSTRACT

In spite of advances in conventional four-plasmid transient transfection methods and development of inducible stable production cell lines, production of replication-defective lentiviral vectors in clinical scale has been challenging. Baculovirus technology offers an alternative to scalable virus production as a result of fast and easy production of baculoviruses, efficient transduction of mammalian cells and safety of the baculoviruses. As a first step toward scalable lentiviral production system, we have constructed four recombinant baculoviruses: the BAC-transfer virus expresses green fluorescent protein (GFP) as a transgene and BAC-gag-pol, BAC-vesicular stomatitis virus glycoprotein G and BAC-rev express all elements required for a safe lentivirus vector generation. Following 293T cell transduction with recombinant baculoviruses functional lentiviruses were produced. Different baculovirus concentrations, mediums and transduction times were used to find optimal conditions for lentivirus production. The unconcentrated lentiviral titers in cell culture mediums were on average 2.5 x 10(6) TU ml(-1), which are comparable to titers of the lentiviruses produced by conventional four-plasmid methods. Lentiviruses produced by baculovirus method transduced HeLa cells and showed sustained GFP expression. No evidence of the formation of replication competent lentiviruses was detected by p24 enzyme-linked immunosorbent assay. Our results show that baculoviruses are an attractive alternative for the production of lentiviruses in mammalian cells.


Subject(s)
Baculoviridae/genetics , Genetic Therapy/methods , Genetic Vectors/genetics , Lentivirus/genetics , Organisms, Genetically Modified , Cell Line , Cloning, Molecular , Flow Cytometry , Gene Expression , Green Fluorescent Proteins/genetics , HeLa Cells , Humans , Microscopy, Fluorescence , Transduction, Genetic/methods , Transgenes , Virology/methods , Virus Replication
4.
Bone ; 35(2): 439-47, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15268895

ABSTRACT

Physical activity is an important factor in attaining bone mass. Our aim was to investigate if low to moderate intensity exercise affects bone resorption [serum tartrate-resistant acid phosphatase (TRAP) 5b activity] and formation (serum osteocalcin concentration) in a randomized controlled exercise intervention trial in Finnish middle-aged men. In addition, the relations of these bone turnover markers with bone mineral density (BMD) and serum sex hormone concentrations [circulating testosterone (T), estradiol (E2), and sex hormone-binding globulin (SHBG) concentrations] were evaluated. Serum TRAP 5b activity and osteocalcin concentration were measured at randomization and after 1 and 4 years of the exercise intervention. BMDs of the lumbar spine (L2-L4), femoral neck, and total proximal femur were measured with a dual-energy X-ray absorptiometry (DXA). At randomization, TRAP 5b activity was strongly correlated with the osteocalcin concentration (Spearman r = 0.541, P < 0.0001). In addition, TRAP 5b activity was significantly correlated with proximal femur BMD values (r = -0.201, P = 0.018) and osteocalcin concentration with femoral neck and proximal femur BMD values (r = -0.187, P = 0.028; r = -0.240, P = 0.005, respectively). Serum E2, free E2, and free T concentrations were inversely correlated with both bone turnover markers. After 1 year of exercise intervention, TRAP 5b activity was significantly lower in the exercise than reference group (P = 0.006). However, after 4 years of exercise intervention, the difference was no longer statistically significant. There were no differences in the osteocalcin concentrations between the study groups during the intervention. Our results show a connection between serum TRAP 5b activity and osteocalcin concentration. Furthermore, our results suggest that low to moderate exercise intervention and serum sex hormone concentrations may induce changes in bone metabolism in middle-aged men. However, exercise-induced effects on bone metabolism should be confirmed in other randomized controlled exercise trials taking into account exercise intensity and dose-response issues.


Subject(s)
Bone Density , Bone and Bones/metabolism , Estradiol/blood , Exercise , Sex Hormone-Binding Globulin/metabolism , Testosterone/blood , Absorptiometry, Photon , Acid Phosphatase/blood , Anthropometry , Finland , Humans , Isoenzymes/blood , Male , Middle Aged , Osteocalcin/blood , Tartrate-Resistant Acid Phosphatase
5.
Bone ; 34(2): 320-9, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14962810

ABSTRACT

Glucocorticoids have marked effects on bone metabolism, and continued exposure of skeletal tissue to excessive amounts of these steroids results in osteoporosis. Therefore, in the present proteomic study, we characterized the potential effects of glucocorticoids on protein expression in human osteoblastic cells. Using two-dimensional gel electrophoresis and mass spectrometry, we identified an increased expression of glutamine synthetase (GS) in dexamethasone (Dex)-treated human MG-63 osteosarcoma cells. GS is an enzyme catalyzing the conversion of glutamate and ammonia to glutamine. Intracellular and extracellular glutamate levels may be important in cell signalling mediated by glutamate transporters and receptors which have recently been found in bone cells. The induction of GS protein by Dex was accompanied by an increase in mRNA level and enzyme activity. Dex induction of GS was also mediated by glucocorticoid receptors (GRs) because it was blocked by the GR antagonist RU-38486. In addition, Dex induction of GS expression was partially blocked by cyclohexamide indicating that it at least partly required new protein synthesis. GS induction by Dex was not associated with apoptosis as determined by Bax/Bcl-2 ratio and DNA staining. In addition to MG-63 cells, Dex induction of GS was also observed in human G-292 osteosarcoma cells as well as conditionally immortalized human preosteoblastic (HOB-03-C5) and mature osteoblastic (HOB-03-CE6) cells. However, in two other human osteosarcoma cell lines, SaOS-2 and U2-OS, GS expression was not affected by Dex. This observation may be explained by the lower levels of GR protein in these cells. In summary, this is the first report of the regulation of GS expression by glucocorticoids in bone cells. The role of GS in bone cell metabolism and glucocorticoid action on the skeleton is not yet known, but as a modulator of intracellular glutamate and glutamine levels, it may have an important role in these processes.


Subject(s)
Dexamethasone/pharmacology , Glucocorticoids/pharmacology , Glutamate-Ammonia Ligase/biosynthesis , Osteoblasts/drug effects , Apoptosis/physiology , Cells, Cultured , Electrophoresis, Gel, Two-Dimensional , Glutamate-Ammonia Ligase/drug effects , Hormone Antagonists/pharmacology , Humans , Immunoblotting , Mass Spectrometry , Osteoblasts/metabolism , Protein Synthesis Inhibitors/pharmacology , Reverse Transcriptase Polymerase Chain Reaction
6.
Bone ; 32(4): 412-20, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12689685

ABSTRACT

Our aim was to investigate associations of the polymorphic loci of androgen receptor (AR), aromatase CYP19, and estrogen receptor alpha (ERalpha) genes with bone mineral density (BMD) in a four-year controlled randomized exercise intervention trial in Finnish middle-aged men. Additionally, we studied whether the gene polymorphisms affect circulating testosterone (T), estradiol (E(2)), and sex hormone-binding globulin concentrations. The polymorphic CAG repeat of the AR gene, the TTTA repeat of the human aromatase gene, and the PvuII site of the ERalpha gene were analyzed. BMDs of the lumbar spine (L2-L4), femoral neck, and total proximal femur were measured with a dual-energy X-ray absorptiometry (DXA). In the exercise group, the subjects with the ERalpha gene PP or Pp genotypes showed an increase (+6.5 and +5.1%, respectively) in lumbar spine BMDs (P = 0.007; repeated measures ANOVA) during intervention, while there was no change in the subjects with the pp genotype. The long TTTA repeat (TTTA(9-12)) in aromatase gene was associated with greater height (P = 0.026) and lower BMI (P = 0.029) values than the short TTTA repeat (TTTA(6-8)). With regard to the AR gene, no statistically significant differences in bone properties were found between the genotypes. There were no significant associations of any analyzed polymorphic sites with the serum sex steroid hormone concentrations in the exercise or reference group. In conclusion, the Finnish middle-aged men with ERalpha PP or Pp genotypes appear to have increased BMD values in the lumbar spine. This increase may reflect a predisposition to age-related degenerative changes in the spine. In addition, the AR CAG repeat and aromatase TTTA repeat do not modify the effect of regular aerobic exercise on BMD.


Subject(s)
Aromatase/genetics , Bone Density/genetics , Exercise/physiology , Receptors, Androgen/physiology , Receptors, Estrogen/genetics , Body Height/genetics , Estradiol/blood , Estrogen Receptor alpha , Finland , Genotype , Humans , Male , Middle Aged , Polymerase Chain Reaction , Polymorphism, Genetic , Sex Hormone-Binding Globulin/analysis , Testosterone/blood
7.
Arch Dis Child Fetal Neonatal Ed ; 85(3): F214-6, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11668167

ABSTRACT

Genetic determinants of bone mineral content in prematurely born children at 3 months and 9-11 years of age were studied. The findings suggest that multiple genes are involved in the regulation of site specific bone mass accumulation during childhood.


Subject(s)
Bone Density/genetics , Infant, Premature/physiology , Absorptiometry, Photon/methods , Alleles , Analysis of Variance , Body Weight , Child , Electrophoresis, Agar Gel/methods , Genotype , Humans , Infant , Infant, Newborn , Insulin-Like Growth Factor I/genetics , Polymerase Chain Reaction/methods , Polymorphism, Restriction Fragment Length , Receptors, Calcitriol/genetics , Receptors, Estrogen/genetics
8.
Steroids ; 66(3-5): 223-5, 2001.
Article in English | MEDLINE | ID: mdl-11179729

ABSTRACT

Selected 20-epi and 20-normal vitamin D(3) analogs were studied. First, point mutations were introduced into human vitamin D receptor (VDR) to identify residues important for ligand binding. In helices three, four and five, His229, Asp232, Ser237 and Arg274 seem to have an important role in the binding of calcitriol. Surprisingly, the 20-epi analog MC 1288 did not bind to Ser237. Second, the effects of analogs on VDR degradation were studied. The transcriptionally active 20-epi analogs protected VDR against degradation more efficiently than the 20-normal analogs and calcitriol. With proteasome inhibitor MG-132 formation of Sug-1-RXRbeta-VDR-VDRE complex was detected. The 20-epi analogs effectively prevented its formation. Thus, the 20-epi analogs induce a VDR conformation, which prevents binding of factors mediating VDR degradation. Third, the analogs were found to be powerful regulators of cell cycle progression in MG-63 cells. They arrested cell cycle in the G0/G1 phase at lower concentrations and earlier time points than calcitriol. This was accompanied by hypophosphorylation of Rb followed by strong inhibition of Cdk2 activity. This correlated with increased levels of p27. Cdk2 and cyclin E levels were downregulated but those of p21 and cyclin D1 were not affected. Thus, a similar sequence of events with calcitriol and the analogs in inhibiting MG-63 cell growth was detected but the analogs had much longer lasting and stronger effects than calcitriol. A unifying scheme for the varying effects of vitamin D(3) analogs is presented.


Subject(s)
Cholecalciferol/analogs & derivatives , Cholecalciferol/pharmacology , Animals , Binding Sites/genetics , Cell Cycle/drug effects , Humans , Receptors, Calcitriol/drug effects , Receptors, Calcitriol/genetics , Receptors, Calcitriol/metabolism
9.
J Bone Miner Res ; 15(12): 2479-86, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11127213

ABSTRACT

Genetic factors regulate bone mineral density (BMD) and possibly development of osteoporosis. It has been suggested that estrogen receptor alpha (ERalpha) genotype is associated with BMD, but the association between ERalpha genotype, fracture risk, and postmenopausal hormone replacement therapy (HRT) has not been studied. Therefore, we evaluated whether ERalpha polymorphism is associated with fracture risk in a 5-year trial with HRT in a population-based, randomized group of 331 early postmenopausal women. The participants consisted of two treatment groups: the HRT group (n = 151) received a sequential combination of 2 mg of estradiol valerate (E2Val) and 1 mg of cyproterone acetate with or without vitamin D3, 100-300 IU + 93 mg calcium as lactate per day; and the non-HRT group (n = 180) received 93 mg of calcium alone or in combination with vitamin D3, 100-300 IU/day. All new symptomatic, radiographically defined fractures were recorded. Pvu II restriction fragment length polymorphism of the ERalpha was determined using polymerase chain reaction (PCR). In all, 28 women sustained 33 fractures during the approximately 5.1-year follow-up. In the HRT group, the ERalpha genotype (PP, Pp, and pp) was not significantly associated with fracture risk (p = 0.138; Cox proportional hazards model). When the genotype was dichotomized (PP + Pp vs. pp), the incidence of new fractures in the HRT group was significantly reduced in women with the P allele (p = 0.046) with the relative risk (HR) of 0.25 (95% CI, 0.07-0.98), in comparison with the non-P allele group. After adjustment for time since menopause and previous fracture, the association between the dichotomous genotype and fracture risk persisted with HR of 0.24 (95% CI, 0.06-0.95;p = 0.042). In the non-HRT group, the ERalpha genotype was not significantly associated with fracture risk. During HRT, women with the pp genotype have a greater fracture risk than those with the P allele. The results suggest that the pp genotype is a relatively hormone-insensitive genotype, and it appears that women with the P allele may benefit more from the protective effect of HRT on fracture risk than women with the pp genotype.


Subject(s)
Estradiol/analogs & derivatives , Estrogen Replacement Therapy , Fractures, Bone/prevention & control , Osteoporosis, Postmenopausal/genetics , Osteoporosis, Postmenopausal/prevention & control , Receptors, Estrogen/genetics , Androgen Antagonists/therapeutic use , Cyproterone Acetate/therapeutic use , Estradiol/therapeutic use , Estrogen Receptor alpha , Female , Follow-Up Studies , Fractures, Bone/etiology , Genotype , Humans , Middle Aged , Osteoporosis, Postmenopausal/complications , Polymorphism, Genetic , Risk
10.
Genes Dev ; 14(23): 2938-43, 2000 Dec 01.
Article in English | MEDLINE | ID: mdl-11114883

ABSTRACT

The developmental ontogeny of the vascular system (consisting of xylem, phloem and [pro]cambium) is poorly understood despite its central role in plant physiology. We show that in the Arabidopsis root meristem, xylem cell lineages are specified early, whereas phloem and procambium are established through a set of asymmetric cell divisions. These divisions require the WOODEN LEG (WOL) gene. The WOL gene encodes a novel two-component signal transducer with an unusual tandem arrangement of two receiver domains. It is expressed specifically in the vasculature from the early stages of embryogenesis on, consistent with a role as a sensor for vascular morphogenesis.


Subject(s)
Arabidopsis/enzymology , Arabidopsis/growth & development , Protein Kinases/metabolism , Amino Acid Sequence , Arabidopsis/genetics , Arabidopsis/metabolism , Base Sequence , Cell Division , DNA, Plant , Histidine Kinase , Molecular Sequence Data , Morphogenesis , Plant Roots/growth & development , Protein Kinases/genetics , Protein Kinases/physiology
11.
J Bone Miner Res ; 15(2): 315-21, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10703934

ABSTRACT

Genetic factors regulate bone mineral density (BMD) and possibly the development of osteoporosis. An association between estrogen receptor (ER) polymorphism, BMD, and postmenopausal hormone replacement therapy (HRT) has not been established. Therefore, we studied the influence of the ER genotype on BMD before and after a 5-year HRT in a placebo-controlled, population-based, randomized group of 322 early postmenopausal women. The participants were randomized into two treatment groups: the HRT group (n = 145) received a sequential combination of 2 mg estradiol valerate and 1 mg CPA with or without vitamin D3, 100-300 IU + 500 mg calcium lactate/day (equal to 93 mg Ca2+), and the non-HRT group (n = 177) received calcium lactate, 500 mg alone or in combination with vitamin D3, 100-300 IU/day. PvuII restriction fragment length polymorphism (RFLP) of the ERalpha was determined using polymerase chain reaction (PCR). BMDs of the lumbar spine (L2-4) and proximal femur were measured by using dual-energy X-ray absorptiometry (DXA). At the baseline, there were no significant differences in the lumbar or femoral neck BMDs between the three ER PvuII genotype groups (PP, Pp, pp). After 5 years, the BMD of the femoral neck remained unaltered and that of the lumbar spine increased by 1.7% in the HRT group, whereas both BMDs were decreased by 4-5% in the non-HRT group. The ER genotype did not modulate the femoral neck BMD change during the follow-up. In contrast, in the non-HRT-group the lumbar spine BMD decreased more in subjects with the ER genotypes PP (6.4%) and Pp (5.2%) than in subjects with the pp genotype (2.9%) (p = 0.002). In the HRT group, the relative changes of the lumbar spine BMD were similar in all three ER genotype groups. Thus without HRT, the pp genotype was associated with a smaller decrease in the lumbar spine BMD than the Pp and PP genotypes. Long-term HRT seemed to eliminate the ER genotype-related differences in the BMD. We conclude that subjects with the ER PvuII genotypes PP and Pp may have a greater risk of relatively fast bone loss after menopause than those with the pp genotype and that they may preferentially derive benefit from HRT.


Subject(s)
Hormone Replacement Therapy , Osteoporosis, Postmenopausal/genetics , Polymorphism, Genetic , Receptors, Estrogen/genetics , Deoxyribonucleases, Type II Site-Specific , Female , Finland/epidemiology , Humans , Osteoporosis, Postmenopausal/epidemiology , Osteoporosis, Postmenopausal/etiology
12.
J Cell Biochem ; 76(4): 548-58, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10653974

ABSTRACT

We and others have previously shown that selected vitamin D analogs potentiate the vitamin D receptor (VDR) mediated transcription much more efficiently than the natural hormone itself. Here we show that the transcriptionally active 20-epi analogs, namely KH 1060 and MC 1288, protect VDR against degradation more efficiently than calcitriol at 10(-10) M concentration (VDR t(1/2) > 48 h, 17 h, and 10 h, respectively). The conformationally epi-like analog EB 1089 did not significantly alter the half-life of VDR (10.3 h), but retained the VDR levels over longer periods of time than calcitriol. The transcriptionally weak analog GS 1558, on the other hand, enhanced VDR degradation even more than what was observed with the unliganded receptor (t(1/2) 4.5 h and 5 h, respectively). Inhibition of proteasome activity by the inhibitor MG-132 resulted in a marked increase in the VDR levels in cells treated with the vehicle or GS 1558 (2.5-fold and 2.7-fold, respectively), more than twice the levels observed in the presence of calcitriol or EB 1089 (1.2-fold and 1.1-fold, respectively). MG-132 treatment did not increase the VDR levels in cells treated with KH 1060 or MC 1288. The electrophoretic mobility shift assay (EMSA) with nuclear extracts from MG-132-treated cells revealed formation of a high-molecular-weight RXRbeta-VDR-VDRE complex, which also contained Sug1. In the presence of calcitriol, 34% of total VDR in its DNA binding state was present in this complex. The 20-epi analogs effectively prevented the formation of this complex, since, in this case, only 16% of total VDR was found in this complex. These results suggest that KH 1060 and MC 1288 induce a VDR conformation, which prevents binding of proteins mediating receptor degradation. As a result, the regulation of VDR degradation differs from that found with the calcitriol-VDR complex resulting in superactive transcriptional action of the analogs.


Subject(s)
Receptors, Calcitriol/metabolism , Vitamin D/analogs & derivatives , Calcitriol/analogs & derivatives , Calcitriol/pharmacology , Calcium Channel Agonists/pharmacology , Cysteine Endopeptidases/metabolism , DNA-Binding Proteins/analysis , Enzyme Inhibitors/pharmacology , Humans , Leupeptins/pharmacology , Models, Biological , Molecular Conformation , Molecular Structure , Multienzyme Complexes/metabolism , Nuclear Proteins/metabolism , Osteoblasts/metabolism , Osteocalcin/genetics , Proteasome Endopeptidase Complex , Protein Binding , Tumor Cells, Cultured
13.
J Cell Biochem ; 68(2): 151-63, 1998 Feb 01.
Article in English | MEDLINE | ID: mdl-9443071

ABSTRACT

Change in the synthesis of type I collagen, the major extracellular matrix component of skin and bone, are associated with normal growth, tissue repair processes, and several pathological conditions. Expression of the COL 1A1 gene is regulated by transcriptional and post-transcriptional mechanisms. However, the hormonal regulation of type I collagen synthesis in human bone has not been well characterized. We have studied the influence of calcitriol, dexamethasone, retinoic acid, and estradiol on the COL 1A1 gene expression by determining the secretion of the C-terminal propeptide (PICP) and the levels of alpha 1(I) procollagen mRNA in cultured human MG-63 and SaOs-2 osteoblast-like osteosarcoma cells. Similar experiments were also performed with respect to expression of the nuclear proto-oncogenes, c-fos and c-jun, in MG-63 cells. In MG-63 cells, calcitriol stimulated the synthesis and secretion of PICP. The alpha 1(I) procollagen mRNA level was elevated with no effect on message stability, indicating a transcriptional mechanism of regulation. In contrast, dexamethasone treatment was accompanied by an accelerated rate of alpha 1(I) procollagen mRNA turnover, observed as decreased amounts of the message and the secreted PICP, implying a posttranscriptional regulation. Retinoic acid, in turn, decreased the levels of alpha 1(I) procollagen mRNA and secreted PICP by slowing down transcription of the COL1A1 gene without any effect on message stability. The ability of these hormones to regulate the alpha 1(I) transcripts was sensitive to puromycin treatment, suggesting an involvement of an induced mediator protein in the action of the hormones on the COL1A1 gene. Both dexamethasone and calcitriol rapidly but transiently increased the expression of the c-fos and c-jun proto-oncogenes. Neither proto-oncogene responded to retinoic acid treatment with significant changes in mRNA levels. Estradiol treatment was found to have no influence on type I procollagen synthesis. In SaOs-2 cells, which are not as well differentiated as the MG-63 cells, calcitriol and dexamethasone did not influence type I procollagen synthesis. Retinoic acid as well as estradiol reduced collagen gene expression in these cells. These findings suggest that hormonal effects on type I procollagen synthesis may depend on the maturational state of the osteoblastic cells that express different regulatory factors and receptors, resulting in, in each case, a finely adjusted rate of gene expression.


Subject(s)
Procollagen/drug effects , Procollagen/genetics , Steroids/pharmacology , Administration, Topical , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacology , Calcitriol/administration & dosage , Calcitriol/pharmacology , Dexamethasone/administration & dosage , Dexamethasone/pharmacology , Dose-Response Relationship, Drug , Estradiol/pharmacology , Gene Expression Regulation , Glucocorticoids , Humans , Osteosarcoma , Proto-Oncogene Mas , Proto-Oncogene Proteins c-fos/drug effects , Proto-Oncogene Proteins c-fos/metabolism , Proto-Oncogene Proteins c-jun/drug effects , Proto-Oncogene Proteins c-jun/metabolism , Steroids/administration & dosage , Tretinoin/administration & dosage , Tretinoin/pharmacology , Tumor Cells, Cultured
14.
Eur J Biochem ; 238(1): 97-103, 1996 May 15.
Article in English | MEDLINE | ID: mdl-8665957

ABSTRACT

We have compared the actions of calcitriol and its three synthetic analogs, 20-epi-22-oxa-24a,26a,27a-trihomo-1 alpha,25-dihydroxyvitamin D3 (KH 1060), 1 alpha,24S-(OH)2-22-ene-26,27-cyclopropyl vitamin D3 (MC 903) and 20-epi-1 alpha,25-dihydroxyvitamin D3 (MC 1288), on the expression of two marker genes of differentiated osteoblasts, namely alkaline phosphatase and osteocalcin, using human MG-63 osteosarcoma cells. Calcitriol and the analogs had qualitatively similar stimulatory effects on target-gene activation. Quantitatively, MC 903 behaved in most experiments essentially as the parent compound calcitriol. In vitamin D receptor/DNA complex formation MC 903, however, was more potent than calcitriol. In contrast, the 20-epi analogs, KH 1060 and MC 1288, were much more potent even at lower concentrations, than calcitriol and MC 903 in stimulating alkaline phosphatase activity, osteocalcin mRNA synthesis and osteocalcin secretion. The stimulation occurred to a greater degree and for a longer period than with calcitriol. This effect was apparently mediated by stronger and longer lasting binding of the vitamin D receptor to the osteocalcin vitamin D responsive element by the 20-epi analogs. After a 6-h treatment and during subsequent culture without hormone, the effects of the 20-epi analogs were also stronger and lasted longer than those with calcitriol or MC 903. Collectively, at comparable and lower concentrations, the 20-epi analogs, KH 1060 and MC 1288, mediate much stronger and longer lasting stimulatory effects than calcitriol or its analog MC 903 on target-gene expression associated with the differentiated phenotype of the MG-63 human osteosarcoma cells.


Subject(s)
Calcitriol/analogs & derivatives , Calcitriol/pharmacology , Gene Expression Regulation, Neoplastic , Osteocalcin/genetics , Osteosarcoma/drug therapy , Alkaline Phosphatase/drug effects , Alkaline Phosphatase/genetics , Alkaline Phosphatase/metabolism , Base Sequence , Binding Sites , Cell Differentiation/drug effects , Cell Differentiation/genetics , Dose-Response Relationship, Drug , Humans , Molecular Sequence Data , Osteocalcin/drug effects , Osteocalcin/metabolism , Osteosarcoma/pathology , Promoter Regions, Genetic , RNA, Messenger/analysis , Receptors, Calcitriol/drug effects , Receptors, Calcitriol/metabolism , Stereoisomerism , Time Factors , Transcriptional Activation , Tumor Cells, Cultured
15.
Biochem Pharmacol ; 51(7): 887-92, 1996 Apr 12.
Article in English | MEDLINE | ID: mdl-8651937

ABSTRACT

EB 1089 (1 alpha,25-dihydroxy-22,24-diene-24,26,27-trihomovitamin D3) is a novel, synthetic analog of calcitriol, characterized by two extra double bonds in its side chain. It is less potent than calcitriol in its calcemic action, but is an order of magnitude more potent in its antiproliferative action. The aim of this study was to determine the ability of EB 1089 to induce the well-known biological effects of calcitriol in MG-63 human osteosarcoma cells (i.e. by inhibiting cell proliferation and by induction of differentiation). Both calcitriol and EB 1089 significantly decreased cell growth after 2 days in culture. At 5 days, however, Eb 1089 was more potent than the natural hormone in inhibiting the proliferation of MG-63 cells. Potent effects of EB 1089 on cell differentiation were also seen in the stimulation of alkaline phosphatase activity, cellular vitamin D receptor mRNA levels, and medium osteocalcin synthesis. EB 1089 was clearly more effective than calcitriol in stimulating alkaline phosphatase activity and osteocalcin synthesis. In gel shift assays, the binding of vitamin D receptor to the composite AP-1 plus vitamin-D responsive promoter region of the human osteocalcin gene after EB 1089 treatment was stronger and longer-lasting than after calcitriol treatment.


Subject(s)
Antineoplastic Agents/pharmacology , Calcitriol/analogs & derivatives , Calcitriol/pharmacology , Cell Differentiation/drug effects , Vitamin D/chemistry , Base Sequence , Humans , Molecular Sequence Data , Osteosarcoma/drug therapy , Time Factors , Tumor Cells, Cultured , Vitamin D/analogs & derivatives
18.
Biochem Biophys Res Commun ; 205(2): 1179-86, 1994 Dec 15.
Article in English | MEDLINE | ID: mdl-7802648

ABSTRACT

The effects of steroid and thyroid hormones are mediated by intracellular hormone receptors. An important mechanism modulating target tissue responsiveness to hormones is homologous and heterologous regulation of the receptors. We have characterized the expression of steroid hormone receptors in human MG-63 osteosarcoma cells. The MG-63 cells express receptor mRNAs for glucocorticoids, estrogen, retinoic acid, and 1,25(OH)2D3. We found that only the vitamin D receptor (VDR) mRNA concentration was influenced by the hormones. The stability of the VDR message was identical in control, dexamethasone- and estradiol-treated cells. On the other hand, both 1,25(OH)2D3 and retinoic acid separately stabilized the VDR mRNA levels increasing the apparent half-life by 11 h and 6 h, respectively. The VDR protein levels, however, as measured by immunoprecipitation, increased only after the 1,25(OH)2D3 treatment.


Subject(s)
Gene Expression/drug effects , Receptors, Calcitriol/biosynthesis , Receptors, Steroid/biosynthesis , Steroids/pharmacology , Blotting, Northern , Bone Neoplasms , Calcitriol/pharmacology , Cell Line , Dexamethasone/pharmacology , Estradiol/pharmacology , Humans , Kinetics , Osteosarcoma , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Receptors, Estrogen/biosynthesis , Receptors, Glucocorticoid/biosynthesis , Receptors, Retinoic Acid/biosynthesis , Time Factors , Tretinoin/pharmacology , Tumor Cells, Cultured
19.
J Steroid Biochem Mol Biol ; 43(7): 649-57, 1992 Dec.
Article in English | MEDLINE | ID: mdl-1472457

ABSTRACT

Rabbit and chicken antibodies were raised against two peptides synthesized according to the structure of human 1,25-dihydroxyvitamin D3 receptor (hVDR): rabbit alpha hVDR-103 against the N-terminal amino acids 5-18 and alpha hVDR-104 against the amino acids 172-186 in the hinge region and chicken alpha hVDR-cab11 against the amino acids 172-186, respectively. The specificity of the antibodies was tested by peptide saturation, SDS-PAGE immunoblotting, gel shift assay and sucrose gradient centrifugation. Immunoblotting of a soluble extract (cytosol) from osteosarcoma cell line MG-63 showed a single band with an M(r) of about 48,000 and human intestine cytosol a broad band (50-63,000) for both antibodies. The antibodies recognized activated (3.2S) hVDR by shifting the centrifugation sedimentation profile to 5-6S. The antibodies showed nuclear immunostaining of unoccupied VDR in human osteosarcoma cells MG-63, U2-Os and SaOs-2. The immunoreaction could be saturated with the corresponding synthetic peptide. In immunoblot alpha hVDR-103 reacted with human and rat VDR, whereas alpha hVDR-104 recognized human VDR only. Similarly in immunohistochemistry, alpha hVDR-103 showed staining with hVDR and rVDR, whereas alpha hVDR-104 reacted only with hVDR. All antibodies recognized the native hVDR as verified with sucrose gradient centrifugation or immunoprecipitation but only alpha hVDR-103 and alpha hVDR-cab11 in gel shift assay of hVDR associated with the vitamin D-responsive element of human osteocalcin gene promoter.


Subject(s)
Receptors, Calcitriol , Receptors, Steroid/immunology , Amino Acid Sequence , Animals , Antibodies/chemistry , Antibody Specificity , Centrifugation, Density Gradient , Chickens , Female , Humans , Immunoblotting , Immunohistochemistry , Male , Molecular Sequence Data , Osteosarcoma/immunology , Peptides/immunology , Precipitin Tests , Rabbits , Tumor Cells, Cultured
20.
Mol Cell Endocrinol ; 76(1-3): 149-59, 1991 Apr.
Article in English | MEDLINE | ID: mdl-1820970

ABSTRACT

We have previously shown that osteocalcin synthesis is readily induced by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in MG-63 human osteosarcoma cells (Mahonen et al. (1990) Biochim. Biophys. Acta 1048, 30-37). In the present study, the regulation of osteocalcin synthesis by other hormones of the steroid-thyroid hormone family (retinoic acid, 17 beta-estradiol, triiodothyronine, and dexamethasone) was examined. We found that the other hormones alone had no effects on medium osteocalcin and osteocalcin mRNA concentrations by 96 h of treatment. Compared with 1,25(OH)2D3, however, the combination of 1,25(OH)2D3 with dexamethasone resulted in a greatly reduced medium osteocalcin concentration. Also estradiol and triiodothyronine diminished the stimulatory effect of 1,25(OH)2D3. In contrast, the combination of 1,25(OH)2D3 with retinoic acid resulted in an increased medium osteocalcin concentration. The inhibition of osteocalcin synthesis by dexamethasone and triiodothyronine was accompanied by decreased osteocalcin mRNA levels. Retinoic acid and estradiol, however, did not influence the 1,25(OH)2D3-induced osteocalcin mRNA levels. To examine the specificity of the hormonal effects, the activity of alkaline phosphatase was determined. Both baseline and 1,25(OH)2D3-stimulated alkaline phosphatase activity was found to be inhibited by all other hormones. These results suggest that the steroidal hormones specifically affect osteocalcin synthesis in osteoblastic bone cells, and that complex interactions occur at the level of transcription and/or translation resulting in each case in a finely adjusted rate of osteocalcin synthesis.


Subject(s)
Calcifediol/physiology , Osteocalcin/biosynthesis , Steroids/physiology , Thyroid Hormones/physiology , Alkaline Phosphatase/metabolism , Cell Division , Dexamethasone/pharmacology , Estradiol/physiology , Humans , Osteosarcoma , RNA, Messenger/biosynthesis , Tretinoin/pharmacology , Triiodothyronine/physiology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...